Drugs / SMZ1
last change Sep 2025 re-read 2 minutes ago

SMZ1

Developed for
wet macular degeneration
Investigated by
SANGMYUNG innovation

Trials 1 · a red edge is where a trial was stopped

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07695207 Sep 2025 → Dec 2027 expected wet macular degeneration SANGMYUNG innovation Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SMZ1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07695207